POlycythemia, Proteins and ErYthropoiesis

Last updated: March 25, 2025
Sponsor: Centre Hospitalier Universitaire Dijon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Red Blood Cell Disorders

Treatment

Collection of tube bottoms from blood samples taken in the clinic

Clinical Study ID

NCT06905106
GIRODON_2024
  • Ages > 18
  • All Genders

Study Summary

Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Persons who have given their non-opposition

Patients with polycythemia:

  • haemoglobin value > 16 g/dl female or > 16.5 g/dl male

  • with a well-identified cause: either primary (polycythemia Vaquez, erythropoietinreceptor or LNK/SH2B3 mutation...) or secondary [cardio-respiratory pathologies,renal pathologies (post-transplant, polycystic kidney disease), metabolicpathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...)

Patients control:

  • persons with a similar pathology to that of polycythemia patients, essentialysecondary, but without polycythemia, i.e. with a haemoglobin value of < 16 g/DL forwomen and < 16.5 g/DL for men

Exclusion

Exclusion Criteria:

  • Person subject to a measure of legal protection (guardianship, tutorship)

  • Person subject to a court order

  • Pregnant, parturient or nursing woman

  • Incapable of expressing consent

  • Minor

Study Design

Total Participants: 400
Treatment Group(s): 1
Primary Treatment: Collection of tube bottoms from blood samples taken in the clinic
Phase:
Study Start date:
September 01, 2024
Estimated Completion Date:
September 30, 2028

Connect with a study center

  • CHU Dijon Bourgogne

    Dijon, 21000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.